GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma

• Status: Recruiting
• Trial end date: 2026-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.

The main purposes of this study include:

① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore.

② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chinese Academy of Sciences

Criteria

Inclusion Criteria:

1. Patients who have been diagnosed with hepatocellular carcinoma.

2. Planned to receive hepatectomy.

3. Liver function Child-Pugh A/B.

4. GPC-3 was validated highly expressed preoperatively.

5. Aged 18 to 75, and the expected lifetime is longer than 6 months.

6. Approved to sign the informed consent.

Exclusion Criteria:

1. Allergic to IRDye800.

2. Enrolled in other trials in the past 3 months.

3. Another malignant tumor was found.

4. Undesirable function of heart, lung, kidney, or any other organs.

5. Unable to tolerate a hepatectomy.

6. The researchers considered inappropriate to be included.